Rewind for Posttraumatic Stress Disorder: A Randomised Controlled Trial

Table 3

Primary and secondary outcome results at 8- and 16-week follow-up for nonimputed data.

		Immediate treatment group			Delayed treatment group
			Mean	SD		Mean	SD
CAPS-5 symptom severity	Baseline	20	36.50	8.24	20	40.15	5.77
	8 weeks	16	18.06	14.96	15	35.00	9.20
	16 weeks	17	16.94	14.51	9	21.33	12.99
PCL-5	Baseline	20	52.65	11.56	19	57.21	12.31
	8 weeks	12	21.25	20.41	16	44.13	14.83
	16 weeks	10	24.50	24.29	7	23.71	21.68
WSAS	Baseline	19	21.16	9.44	18	23.39	9.85
	8 weeks	11	10.27	10.78	16	22.88	9.24
	16 weeks	9	14.67	13.36	6	13.50	13.82
PHQ-9	Baseline	20	14.65	6.17	19	17.74	5.65
	8 weeks	12	5.58	6.72	16	15.06	6.14
	16 weeks	10	7.70	8.56	7	8.29	7.11
GAD-7	Baseline	20	13.10	4.73	19	14.53	4.27
	8 weeks	12	5.75	6.20	16	12.69	4.85
	16 weeks	10	7.20	6.78	7	5.43	4.69
ISI	Baseline	20	17.65	5.96	19	19.00	6.21
	8 weeks	12	10.00	8.42	16	17.06	6.81
	16 weeks	10	11.00	10.85	7	12.57	5.32
Audit-O	Baseline	18	5.61	8.64	17	4.29	5.62
	8 weeks	11	4.36	6.12	16	4.25	4.84
	16 weeks	10	3.40	5.42	7	3.86	4.74
MSPSS	Baseline	20	56.75	15.95	19	54.89	15.81
	8 weeks	12	63.25	14.72	15	52.80	17.80
	16 weeks	10	64.00	16.81	7	54.43	22.10